Summary We investigated 5-azacytidine and five of its analogues for: (1) carcinogenicity, in the male Fischer rat; (2) toxicities using changes in rat weights in vivo and a cytotoxicity assay in vitro; and (3) haemoglobin gene expression, using minor haemoglobin synthesis in sheep, mice and rats. 5-Azacytidine was found to be a complete carcinogen. It increased the incidence of testicular tumours as well as non-testicular tumours in rats treated for 12 months. 5-Azacytidine also had hepatic tumour promoting properties and was able to induce transplacental carcinogenesis when administered to pregnant rats on day 21 of timed pregnancies. None of the other 5 analogues that were tested appeared to be carcinogenic in small experiments. All the analogues which are known to have hypomethylating activity were found to be cytotoxic in vitro; the most potent being 5-azacytidine. As judged by decreased rat weight compared to untreated controls, the fluorinated cytidine analogues and 5'-deoxyazacytidine were more toxic than 5-azacytidine. Altered haemoglobin synthesis was seen in rats and DBA/2J mice, but not in sheep. In mice, where the clearest haemoglobin changes were noted, an increase in minor haemoglobin synthesis was found using both high and low doses of 5-azacytidine, and with 5,6-dihydro-5-azacytidine and 5-aza-2'-deoxycytidine. These last two analogues appear to be relatively non-toxic, noncarcinogenic in these experiments, and retain haemoglobin activating properties with a potency similar to that of 5-azacytidine.
Enzymatic DNA methylation occurs as a postreplicative process, producing, in mammals, only the minor base 5-methylcytosine. The methylation of specific DNA cytosine residues is inversely correlated with transcription of most genes, although there are exceptions. Inhibitors of DNA methylation will often activate previously silent genes and this is the strongest single line of evidence implicating methylation in gene control. There have been several recent reviews of mammalian DNA methylation (Holliday, 1979; Riggs & Jones, 1983; Nyce et al.,1983; Doefler, 1983; Razin et al., 1984; Jones, 1986) , and considering all data, it appears that methylation of DNA cytosine is one among several mechanisms significant in the control of mammalian gene expression (Riggs & Jones, 1983; Doefler, 1983; Razin et al., 1984) , perhaps functioning primarily as a locking mechanism for the stable maintenance of the transcriptionally silent state (Razin & Riggs, 1980) . There has been speculation that DNA methylation changes may play some role in tumour initiation or progression (Holliday, 1979; Riggs & Jones, 1983; Nyce et al., 1983; Jones, 1986) , and some experimental data are now available. Evidence that DNA methylation changes may be associated with tumorigenesis is as follows: (a) The DNA of tumour cells has often been found to be undermethylated compared to the DNA of normal cells (although exceptions have been found) (Lapeyre et al., 1981; Gama-Sosa et al., 1983; Goelz et al., 1985) ; the methylation patterns of some genes that are expressed in tumour cells have been found to be altered in association with increased gene expression (Feinberg & Vogelstein, 1983a, b; Cheah et al., 1984) ; (b) the DNA of tumour metastases is less-methylated than the DNA of primary tumours (Gama-Sosa et al., 1983) ; (c) the DNA of primary malignant tumours is less-methylated than the DNA of benign tumours (Gama-Sosa et al., 1983); transformed cells have been shown to have their metastatic properties altered by the potent inhibitor of DNA methylation, 5-azacytidine (Olsson & Forchammer, 1984; Trainer et al., 1985; Ormerod et al., 1986) ; (e) several carcinogens have been shown to cause demethylation (Boehm & Drahovsky., 1979 Salas et al., 1979; Wilson & Jones, 1983) ; (f) 5-azacytidine, an inhibitor of DNA methylase, has been shown to be a carcinogen in some experimental animal studies (Denda et al., 1985; Stoner et al., 1973; National Cancer Institute 1978; Carr et al., 1984; Vesely & Cihak, 1973) .
5-Azacytidine, an analogue of cytidine in which a nitrogen atom replaces the carbon at position 5 in the pyrimidine ring, was synthesized as an anti-cancer agent (Piskala & Sorm, 1964) . Its known toxicities include immunosuppression, teratogenicity, abortifacient activity and gastrointestinal toxicities, and its biological effects include an inhibition of cell growth and liver regeneration (Cihak, 1974; Hrodek & Vesely, 1971; Weiss et al., 1972; Cihak & Vesely, 1969) , alteration of protein synthesis (Reichman & Penman, 1973) , gene activation (Nyce et al., 1983) , and alteration of the differentiation properties of cells (Constantinides et al., 1977 (Constantinides et al., , 1978 . Recent interest in this drug has centered both on its ability to alter gene activity, and thus its use as a probe in understanding gene regulation, and also on its clinical applications in the induction of otherwise silent genes in the treatment of humans with sickle cell anaemia (Charache et al., 1983) , ,B+thalassemia (Ley et al., 1982) and its potential in the treatment of other heritable diseases. In preliminary experiments, we recently observed that 5-azacytidine might be a complete carcinogen in the F344 rat (Carr et al., 1984) and might also have hepatic tumour promoting activities. In view of the possible application of 5-azacytidine both in the treatment of human malignancies as well as its potential applicability in chronic treatment of humans with non-malignant diseases, we investigated the carcinogenicity of 5-azacytidine in a much larger series of animals and in lower doses. In addition, we also examined other cytidine analogues with known hypomethylating and gene activating properties (Jones & Taylor, 1980) , in the hope of finding an analogue that might retain the gene activating without the carcinogenic properties.
Materials and methods

Experimental animals
Male F344 rats (Simonsen Labs Inc., Gilroy, CA) were fed a basal diet (Purina Lab Chow) and maintained on a 12-h light cycle with unlimited access to food and water, according to the 'Guide to the Care and Use of Laboratory Animals', NIH Publication 85-23. For regimens 1-10, and 13 and 14 (Table I) young adult male rats, at initial weight 160-180g were injected i.p. thrice weekly with either 0.9% NaCl solution (controls) or test drug solution that was freshly dissolved in NaCl 0.9% solution immediately before each injection. Rats were weighed alternate weekly as a guide to their well being. At the end of the experments, rats were sacrificed and the organs were examined grossly, then examined microscopically after fixation. For the study of transplacental carcinogenesis (Regimen 11) pregnant female rats were injected on day 21 of timed pregnancies. Male weanling rats were injected once only 21 days after birth (Regimen 12).
Pathological evaluation A routine gross post mortem examination was performed on all rats at the time of sacrifice. Microscopic examination was performed on a sample of each of the major organs that was taken for fixation in 10% neutral buffered formalin. The tissue specimens were subsequently embedded in paraplast, sectioned at 4,um and stained with hematoxylin and eosin. Histological sections from the organs of all rats were examined blindly fashion by one of the authors (CDW) according to previously-described criteria (Stewart et al., 1959 (Stewart et al., , 1980 . Selected samples, including the livers were subjected to outside pathological review.
Statistical evaluation of results
The data were evaluated for significance using the Fisher's exact test for equality of proportions, with correction for multiple comparisons.
Experimental protocols (Table I) Rats were injected i.p. 3 times weekly with either 0.9% NaCl solution (Regimen 1) or with one of 3 doses of 5-azacytidine, (Regimens 2, 3, 4) starting at a dose of 2.5mg kg -1. These doses were 2.5 (Regimen 2), 0.25 (Regimen 3), and 0.025 mg kg-1 (Regimen 4). The following cytidine analogues were used at the highest dose used for 5-azacytidine (2.5mg kg-1): 5-aza-2'-deoxycytidine (Regimen 5), 5-fluoro-2'-deoxycytidine (Regimen 6), 5-fluorocytidine (Regimen 7), 5,6-dihydro-5-azacytidine (Regimen 8), and 6-azacytidine (Regimen 9). In order to determine whether cytidine in 10-fold excess concentration would compete with 5-azacytidine, cytidine at 25mg kg-1 was administered at the same time as 5-azacytidine (Regimen 10). 5-azacytidine was administered once only at day 21 to timed pregnant rats at a dose of 10mg kg (Regimen 11) or once only at a dose of 5 mg kg to weanling rats (Regimen 12). In order to determine whether 5-azacytidine had hepatic tumour promoting activity, rats were administered a liver cancer initiating dose of diethylnitrosamine 30 mg kg-1 administered 18 h after a partial hepatectomy, after the regimen of Pitot et al. (1978) , and were then given chronic 5-azacytidine 2.5 mg kg-1 i.p. as in regimen 2. Two control regimens were used. Firstly, age controls (Regimen 1) in which rats were administered 0.5 ml NaCl 0.9% i.p. three times weekly, or tetrahydrouridine 27.5mg kg-1 three times weekly (Regimen 14) . Because of the deamination of 5-azacytidine and its analogue in vivo by cytidine deaminase (Chabner et al., 1973) , unstable analogues (Regimens 5, 6, 7, 8) were administered together with tetrahydrouridine (THU) (Neil et al., 1970) , 27.5mg kg-1, by a separate intraperitoneal injection at the same time as each injection of 5-azacytidine.
Haemoglobin studies. (a) Sheep were chosen because of the presence of developmentally-regulated haemoglobin switching (Young et al., 1978) . Two 4-month old female Rambole X Hampshire sheep 60-65 lb wt were purchased and were both bled 100 ml and injected daily through the jugular vein with 5-azacytidine 2 mg kg-1 for 5 days out of 7. Weekly haemoglobin estimations were performed. Haemoglobin electrophoreses were done using cellulose acetate pH 8.6 (Jones & Taylor, 1980) . (b) DBA/2J female mice 6-8 g wt (Jackson Laboratory, Bar Harbor, Maine) were chosen because of the presence of a clearly identifiable, inducible minor haemoglobin (Alter et al., 1982) . They were injected twice weekly i.p. with one of the following: 5-azacytidine 16 or 1.6mg kg -1, 5,6-dihydro-5-azacytidine 6mg kg-1, 5-aza-2'-deoxycytidine 16mg kgi-plus tetrahydrouridine, or NaCl 0.9% (controls). The mice were bled twice weekly and haemoglobin components were separated by cellulose acetate electrophoresis as well as by DEAE cellulose-chromatography (Isolab Inc., Akron, OH). The 2 haemoglobin bands were eluted and separately measured spectrophotometrically. (c) Male F344 rats 160-180 g wt were injected twice weekly with 5-azacytidine 2.5mg kg-1 and bled intermittently (Regimen 2, Table I ). The haemoglobins were separated by cellulose acetate electrophoresis, pH 8.6 (Titan III-H, Helena Labs, Beaumont, TX) and the 5 bands were quantitated using scanning densitometry (Garrick et al., 1975) .
Cytotoxicity assays. Primary monolayer cultures of hepatocytes from male F344 rats 160-180 g wt were prepared as we have previously described (Carr & Laishes, 1981) . After a 3 h attachment period using Leibowitz L-15 medium (GIBCO Labs, Grand Island, NY) and 10% calf serum, the medium was changed to fresh medium containing 10% calf serum and the cells were then incubated without (controls) or with various cytidine analogues at the indicated doses. 
Results
Carcinogenicity
We investigated the carcinogenicity of 3 doses of 5-azacytidine, using 2.5, 0.25, and 0.025mgkg-1. The highest dose chosen was the lowest dose that appeared to be carcinogenic in a preliminary experiment (Carr et al., 1984) . A large excess of rats was used for the 5-azacytidine compared to the control regimen (Regimens 1 and 2, Table  I ) in anticipation of a steady attrition rate at this dose of 5-azacytidine. However, attrition was low and 87% survived. Table II shows that 18% of the rats treated with the highest dose of 5-azacytidine developed non-testicular tumours compared to none in the control group (Regimen 2, Table  II ). In this group, 6 of the 87 evaluable rats also had histological evidence of intraperitoneal fat necrosis. No rats developed tumours at the lower doses of 5-azacytidine (Regimens 3 and 4, Table II ). While 20% of the control rats developed testicular tumours, particularly of the Leydig cell type, as has been reported elsewhere as a feature of aging (Goodman et al., 1979) , 3 times the incidence rate of testicular tumours were seen in the group treated with 2.5mgkg-1 5-azacytidine (Regimen 2, Table II ). The doses for the analogues were 10% of the LD1O dose, obtained in preliminary experiments, except for 5,6-dihydro-5-azacytidine, for which no practicable LD50 dose could be found. No excess of non-testicular tumours was seen with any of the analogues. In the 5,6-dihydro-5-azacytidine group, one rat developed a sarcoma but this was not statistically significant (Regimen 8, Tables II & III) and a single rat had intraperitoneal fat necrosis. It was interesting that in the group of rats treated with 5'-deoxyazacytidine (Regimen 5, Table II ), all 10 developed testicular atrophy, characterized by reduction in size of seminiferous tubules secondary to absence of spermatogenesis, and the presence of oedema and focal interstitial fibrosis. Two of the 10 also showed Leydig cell hyperplasia. In a small group of rats treated with 5-azacytidine plus a 10-fold concentration of cytidine (Regimen 10, Table 2 ) no excess of nontesticular tumours were noted. In the group of rats that received a single initiating dose of the liver carcinogen DEN (Regimen 13, Table II ), all the surviving rats developed hyperplastic liver nodules and a high incidence of non-hepatic, non-testicular primary tumours. Previous work has established that low single DEN doses after a two-thirds partial hepatectomy do not result in liver tumours without subsequent tumour promotion (Carr et al., 1984; Pitot et al., 1978) . Tetrahydrouridine control rats did not develop any excess of non-testicular tumours nor did they show testicular atrophy (Regimen 14). In a test for transplacental carcinogenicity, timed pregnant rats were given a single large dose of 5-azacytidine on the last day of their pregnancy. Earlier periods were not used because of the known fetotoxicity of 5-azacytidine (Schmahl et al., 1985 and our unpublished data). A high incidence of non-testicular primary tumours was noted (3 male, 1 female) but no excess of testicular tumours was found (Regimen 11, Table II ). When 5-azacytidine was given as a single dose to weanling rats (Regimen 12, Table II), a single rat developed a nontesticular tumour.
Spectrum of tumour types
The sepctrum of primary tumour types that was induced in response to chronic administration for the various cytidine analogues is shown in Table III . Tumours were those of the lymphoid system, kidney, lung, skin at the site of injection, sarcomas and mesotheliomas. Hyperplastic liver nodules were found in the rats which were treated with 5-azacytidine after a single initiating dose of the hepatic carcinogen diethylnitrosamine (Regimen 13, Table III ).
Cytotoxicity of cytidine analogues Using a primary monolayer culture system of freshly isolated normal rat hepatocytes to test the cytocidal effects of the cytidine analogues, the cytotoxic actions of the drugs used in the carcinogenicity study were compared (Table IV) . The analogues were incubated with or without the deaminase inhibitor tetrahydrouridine. The results are shown for incubations without tetrahydrouridine, but they were identical in the presence of tetrahydrouridine. The most toxic analogue was 5-azacytidine, followed by 5-fluorocytidine and 5,6-dihydro-5-azacytidine. In this assay, differences of less than 10% are not considered significant. The changes in rat weights over the duration of the experiment with the different analogues are shown in Figure 1 .
Minor haemoglobin induction by cytidine analogues. The ability of cytidine analogues to induce minor haemoglobin synthesis was investigated using 3 different mammalian species: sheep, rats and mice. Advantage was taken of the fact that in sheep and mice, the induction of an otherwise silent or minor haemoglobin can be unambiguously demonstrated. DBA/2J mice were chosen following the report that this inbred strain has a minor haemoglobin comprising -20% of the total haemoglobin, is electrophoretically distinct, and increased synthesis is inducible by an anaemic stress (Alter et al., 1982) . Another species with a foetal haemoglobin switch which is capable of induction is the sheep (Young et al., 1978) . Figure 2 shows the patterns of haemoglobin electrophoresis in the 3 species, sheep, rats and mice. Chronic administration of 2.0mgkg-' 5-azacytidine to 2 sheep for 4 months resulted in no induction of the minor haemoglobin (Figure 2c, d) . However, rats in the carcinogenicity studies of this report, showed qualitative changes with the 5-azacytidine doses used ( Figure  2e-g ). An increase was found in the 2 anodic of the 5 total haemoglobin bands that were visualized on the cellulose acetate electrophoretograms and the disappearance of one band. However, no unambiguous rat haemoglobin changes were seen with any of the other analogues. The significance of the multiple rat haemoglobins is not clear, since they have not been characterized, to our knowledge. In the DBA/2J mice, a greater than 30% increase (Table V) in the minor haemoglobin component was seen in 8 of 9 mice treated with 5-azacytidine 1.6mgkg-1, in 6 of 10 mine treated with 5,6-dihydro-5-azacytidine 1.6mg kg-1, and in 2 of 5 mice treated with 5-aza-2'-deoxy-5-azacytidine 1.6mgkg-1. No significant increase in the minor haemoglobin was seen in the saline controls or the mice treated with 6-azacytidine. 
Discussion
The aims of this study were to investigate the carcinogenicity, toxicity and the haemoglobin activating properties of 5-azacytidine, and to initiate the evaluation of some related analogues to determine whether there was a safer and less toxic analogue that might retain the gene activating properties. The results of this study were severalfold: (1) we confirmed that 5-azacytidine is a complete carcinogen for several tissues and a probable tumour promoter for liver; (2) none of the other analogues tested were significantly carcinogenic, although the sample size was small; (3) a single dose of 5-azacytidine delivered transplacentally to neonates was carcinogenic; (4) several analogues induced minor haemoglobin synthesis in mice, keeping open the possibility that minor haemoglobin induction and carcinogenicity are not irrevocably linked; and (5) only 5-deoxyazacytidine caused dramatic testicular atrophy.
In the main carcinogenicity study of this report, in which 5-azacytidine 2.5mg kg-1 given over 12 months was compared to age-matched control rats (Regimens 1 and 2, Table II), we found that 5-azacytidine induced both a 3-fold increase in the incidence of testicular tumours over the spontaneous incidence which occurs in normal rats with age (Goodman et al., 1979) , and also a large increase in the incidence of non-testicular tumours. In addition, we were able to confirm our preliminary observation that 5-azacytidine appears to enhance the induction of hyperplastic (neoplastic) liver nodules in rats that were treated with a single initiating dose of diethylnitrosamine. Thus, it appears to be a tumour promoter in the liver. We did not find any significant carcinogenic activity of the cytidine analogues which we tested. The concomitant administration of cytidine with 5-azacytidine did not appear to suppress the increased 3. 5-azacytidine 0.25mg kg 1 (10) Months Figure 1 Effects of chronic administration of cytidine analogues on rat weights. Rats were chronically administered cytidine analogues intraperitoneally in 0.9% NaCl solution (experiments) or NaCl solution only (controls). The regimens were as in Table I , and the rats were weighed monthly. The datum points are averages for all the rats in each regimen; controls (0) number of testis tumours, although non-testicular tumours were not seen in a small series (Regimen 10, Table I ). It was of great interest however, that 5-azacytidine induced transplacental carcinogenesis of non-testicular tumours (Regimen 11, Table I ). In another report, 5-azacytidine was found to induce transplacental carcinogenesis in mice (Schmahl et al., 1985) . The results of 5-azacytidine action are expected to be complex. On the one hand, 5-azacytidine is capable of enhancing or inducing the metastatic capacity of various tumour cell lines (Olsson & Forchammer, 1984; Trainer et al., 1985; Ormerod et al., 1986) , activating silent retroviral genomes (Jaenisch et al., 1985) , enhancing the induction by various carcinogens of gamma-glutamyltransferase positive liver foci (Denda et al., 1985) , of altering cellular DNA which is incapable of inducing transformation (Venolia et al., 1982) , and of inducing tumorigenesis in various cells in culture (Venolia et al., 1982; Harrison et al., 1983; Benedict et al., 1977; Marquardt & Marquardt, 1977) , even though it does not appear to be a significant mutagen in mammalian cells (Landolph & Jones, 1982; Frost et al., 1984; Momparler et al., 1984; Delers et al., 1984; Bouck et al., 1984; Jones, 1984) . On the other hand, 5-azacytidine has been shown to induce differentiation in both non-transformed as well as in neoplastic cells in culture (Constantinides et al., 1977 (Constantinides et al., , 1978 Jones & Taylor, 1980; Walker et al., 1984; Creusot et al., 1982; Darmon et al., 1984; Pinto et al., 1984) . 5-Azacytidine is a cell toxin and has been used to treat leukaemia (von Hoff et al., 1976) and can induce the expression of new cell surface antigens and thus increase the effectiveness of immunosurveillance in immunocompetent animals (Frost et al., 1984) . Thus, there appear to be opposite sets of biological actions with respect to carcinogenicity. The explanation may reside in the net effect of the genes that are activated by 5-azacytidine under a given set of experimental conditions. We did not find any evidence of carcinogenicity for 5-azacytidine at log doses below 2.5mgkg-1 in rats. The spectrum of tumour types were similar to that seen previously (Carr et al., 1984; Schmahl et al., 1985) ; viz., tumours of the lymphoid system, skin, lung and kidney, as well as sarcomas and mesotheliomas (Table III) . The skin tumours occurred only at the site of injection, suggesting that there was no need for further drug processing for the carcinogenic action to occur.
Two assays for toxicity were used in our experiments. The first was the change in rat weights with time during the carcinogenicity studies (Figure 1 ). Very few rats died during the experiment and most weight loss was found for the rats treated with the fluorinated cytidine derivatives and with 5-deoxyazacytidine. The second assay was a 24h cytotoxicity study using primary monolayer cultures of freshly prepared normal hepatocytes (Table V) . The 3 drugs with most cytotoxic effects were 5-azacytidine,. 5-fluorocytidine and 5,6-dihydro-5-azacytidine. The addition of tetrahydrouridine to the analogues in cell culture did not influence the toxicity.
The electrophoretic pattern of haemoglobin components of rats was quite complicated and 5 major haemoglobins were visualized, with several minor bands appearing on the densitometry tracings of the electrophoretograms. The changes included an increase in density in the 2 anodic bands and an almost complete disappearance of a third haemoglobin band (Figure 2e-g ). As a result of the complexities inherent in interpreting the multiple haemoglobin bands in rat blood, 2 other species with wellstudied and less complicated haemoglobin bands were used. No minor haemoglobin component induction was found in the 2 sheep that were used. However, DBA/2J female mice which have a major and a minor haemoglobin, showed an increased synthesis of the minor haemoglobin at both high and low doses of 5-azacytidine. This increased minor haemoglobin synthesis in mice was also induced by 5,6-dihydro-5-azacytidine and 5-aza-2'-deoxycytidine (Table V) . Interestingly, increased minor haemoglobin synthesis did not take place within the first few days of cytidine analogue treatment of the mice, but appeared slowly over a 2 month period. Similarly, 5,6-dihydro-azacytidine induces an increase in foetal haemoglobin in humans (Carr et al., 1987) . The mechanism by which cytidine analogues alter minor haemoglobin synthesis is not entirely clear. Although gene activation through DNA methylation changes is a candidate mechanism, other possibilities exist, such as erythroid pool stress. Although we did not observe haematocrit decreases of more than 20%, subtle erythroid stress cannot be excluded.
On comparing the results for minor haemoglobin induction (Table IV) with the carcinogenicity results (Table  II) , it appeared that 5-azacytidine was able to induce an increased minor haemoglobin synthesis in mice and altered haemoglobin synthesis in rats at lower doses than were required for the induction of rat tumours. However, it cannot be assumed that mouse and rat tumorigenic doses will be the same, and separate carcinogenicity studies will be required for the mouse. Two analogues appeared to have haemoglobin activating properties similar to those observed for 5-azacytidine, viz., 5,6-dihydro-5-azacytidine and 5-aza-2',deoxycytidine. These two analogues had no significant carcinogenic activity in our study. 5-aza-2'-deoxycytidine appears particularly promising in this respect, since it was of only moderate toxicity (Table V and Figure 1 ) and did not induce tumours in a small carcinogenicity series, yet retained gene activating properties. These results confirm that 5-azacytidine is a complete carcinogen in the male F344 rat, and show that it has transplacental carcinogenic properties, and can act as a hepatic tumour promoter. No 5-azacytidineinduced tumorigenicity was seen below 2.5mgkg-1 in our study. 5-Azacytidine was'able to alter haemoglobin synthesis in rats and mice. Five other cytidine analogues were also tested for carcinogenicity in experiments with low numbers of rats, in which tumorigenicity was not clearly demonstrable. However, 2 of these apparently non-carcinogenic analogues, 5,6-dihydro-5-azacytidine and 5-aza-2'-deoxycytidine retained the ability to increase minor haemoglobin synthesis. These results suggest that it may be possible to separate the carcinogenic from the potentially useful gene-activating properties' in some cytidine analogues.
From the results reported here and elsewhere (Table VI) there does not appear to be a clear relationship among cytidine analogues between potency as inhibitors of DNA methylation and carcinogenic activity.
